Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC

Agreement provides Vector access to FDA-registered, cGMP facility and supports development of 24 novel shelf-stable peptide formulations targeting the $80.8 billion peptide market MEQUON, Wis., May 11, 2026 /PRNewswire/ -- Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the...